Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas

International Journal of Cancer

Volumn 138, Issue 4, 2016, Pages 891-900

  Manié, Elodie ^a   Popova, Tatiana ^a   Battistella, Aude ^a   Tarabeux, Julien ^a   Caux Moncoutier, Virginie ^a   Golmard, Lisa ^a   Smith, Nicholas K ^a   Mueller, Christopher R ^a,b   Mariani, Odette ^a   Sigal Zafrani, Brigitte ^a   Dubois, Thierry ^a   Vincent Salomon, Anne ^a   Houdayer, Claude ^a   Stoppa Lyonnet, Dominique ^a,c   Stern, Marc Henri ^a  

^a INSTITUT CURIE   (France)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

BRCA1; BRCA2; breast carcinoma; homologous recombination deficiency

Indexed keywords

BEVACIZUMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DNA METHYLATION; DRUG RESPONSE; DRUG SENSITIVITY; GENE; GENE DELETION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC DAMAGE; HOMOLOGOUS RECOMBINATION DEFICIENCY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTANT; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RAD51C GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; WILD TYPE; BREAST TUMOR; CARCINOMA; DNA MICROARRAY; FEMALE; GENETICS; PATHOLOGY; RECOMBINATION REPAIR;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA; CHROMOSOME BREAKAGE; FEMALE; GENES, BRCA2; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECOMBINATIONAL DNA REPAIR; TRANSCRIPTOME;

EID: 84954381684     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29829     Document Type: Article

References (51)

1. Chen S, Parmigiani G., Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33.
2. Easton DF, Pharoah PD, Antoniou AC, et al., Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015; 372: 2243-57.
3. Mavaddat N, Peock S, Frost D, et al., Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-22.
4. Bane AL, Beck JC, Bleiweiss I, et al., BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007; 31: 121-8.
5. Palacios J, Honrado E, Cigudosa JC, et al., ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers. Genes Chromosomes Cancer 2005; 42: 204-5. author reply 6.
6. Roy R, Chun J, Powell SN., BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12: 68-78.
7. van Beers EH, van Welsem T, Wessels LF, et al., Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005; 65: 822-7.
8. Cancer Genome Atlas Research N., Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
9. Esteller M, Silva JM, Dominguez G, et al., Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
10. Hennessy BT, Timms KM, Carey MS, et al., Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28: 3570-6.
11. Polo SE, Jackson SP., Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 2011; 25: 409-33.
12. Turner NC, Reis-Filho JS, Russell AM, et al., BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-32.
13. Drost R, Jonkers J., Opportunities and hurdles in the treatment of BRCA1-related breast cancer. Oncogene 2014; 33: 3753-63.
14. Bouwman P, Jonkers J., The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012; 12: 587-98.
15. Moynahan ME, Jasin M., Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010; 11: 196-207.
16. Antoniou AC, Casadei S, Heikkinen T, et al., Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014; 371: 497-506.
17. Meindl A, H, ellebrand H, Wiek C, et al., Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-4.
18. Golmard L, Caux-Moncoutier V, Davy G, et al., Germline mutation in the RAD51B gene confers predisposition to breast cancer. BMC Cancer 2013; 13: 484.
19. TCGA Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
20. Abkevich V, Timms KM, Hennessy BT, et al., Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107: 1776-82.
21. Pennington KP, Walsh T, Harrell MI, et al., Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764-75.
22. Scott CL, Swisher EM, Kaufmann SH., Poly (adp-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015; 33: 1397-406.
23. O'Sullivan CC, Moon DH, Kohn EC, et al., Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol 2014; 4: 42.
24. Watkins JA, Irshad S, Grigoriadis A, et al., Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014; 16: 211.
25. Popova T, Manie E, Rieunier G, et al., Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72: 5454-62.
26. Birkbak NJ, Wang ZC, Kim JY, et al., Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012; 2: 366-75.
27. Watkins J, Weekes D, Shah V, et al., Genomic complexity profiling reveals that HORMAD1 overexpression contributes to homologous recombination deficiency in triple-negative breast cancers. Cancer Discov 2015; 5: 488-505.
28. Timms KM, Abkevich V, Hughes E, et al., Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014; 16: 475.
29. Isakoff SJ, Mayer EL, He L, et al., TBCRC009: a multicenter phase ii clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902-9.
30. Telli ML, Jensen KC, Vinayak S, et al., Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol 2015; 33: 1895-901.
31. Natrajan R, Mackay A, Lambros MB, et al., A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J Pathol 2012; 227: 29-41.
32. Pecuchet N, Popova T, Manie E, et al., Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas. Int J Cancer 2013; 133: 2834-42.
33. Popova T, Hebert L, Jacquemin V, et al., Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013; 92: 974-80.
34. Vincent-Salomon A, Gruel N, Lucchesi C, et al., Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24.
35. Servant N, Bollet MA, Halfwerk H, et al., Search for a gene expression signature of breast cancer local recurrence in young women. Clin Cancer Res 2012; 18: 1704-15.
36. Vincent-Salomon A, Benhamo V, Gravier E, et al., Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas. PLoS One 2013; 8: e76496.
37. Popova T, Manie E, Stoppa-Lyonnet D, et al., Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009; 10: R128.
38. Houdayer C, Moncoutier V, Champ J, et al., Enhanced mismatch mutation analysis: simultaneous detection of point mutations and large scale rearrangements by capillary electrophoresis, application to BRCA1 and BRCA2. Methods Mol Biol 2010; 653: 147-80.
39. Tarabeux J, Zeitouni B, Moncoutier V, et al., Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model. Eur J Hum Genet 2014; 22: 535-41.
40. Manie E, Vincent-Salomon A, Lehmann-Che J, et al., High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69: 663-71.
41. Hansmann T, Pliushch G, Leubner M, et al., Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet 2012; 21: 4669-79.
42. Dai MH, Wang PL, Boyd AD, et al., Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005; 33:e175.
43. Wu ZJ, Irizarry RA, Gentleman R, et al., A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004; 99: 909-17.
44. Heyer WD, Ehmsen KT, Liu J., Regulation of homologous recombination in eukaryotes. Annu Rev Genet 2010; 44: 113-39.
45. Kuperstein I, Grieco L, Cohen DP, et al., The shortest path is not the one you know: application of biological network resources in precision oncology research. Mutagenesis 2015; 30: 191-204.
46. Haber DA., The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis. Cell 2003; 115: 507-8.
47. Naipal KA, Verkaik NS, Ameziane N, et al., Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res 2014; 20: 4816-26.
48. Thompson D, Easton D., The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004; 9: 221-36.
49. van den Broek AJ, de Ruiter K, van 't Veer LJ, et al., Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. Eur J Hum Genet 2015; 23: 588-95.
50. Tung N, Miron A, Schnitt SJ, et al., Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010; 12: R95.
51. Fong PC, Yap TA, Boss DS, et al., Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-9.